BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing
• A BridgeBio Pharma drug developed for dwarfism increased children’s growth rates in a pivotal clinical trial,meeting the study’s main goaland boosting the daily pill’s chances to